Against this backdrop, life sciences stakeholders should be watching several issues that could shape FDA’s regulatory priorities and the policy environment in the months and years ahead.
FDA LEADERSHIP
Nominations for leadership positions within HHS remain pending, and permanent appointments remain outstanding for certain positions, including the role of FDA commissioner. Acting Commissioner Kyle Diamantas has provided continuity in FDA leadership following significant leadership and staffing changes. However, his tenure as acting commissioner remains subject to the Federal Vacancies Reform Act of 1998. Changes in the leadership and membership of the US Senate Committee on Health, Education, Labor, and Pensions (HELP) following the midterm elections could affect the timing and consideration of a nomination for FDA commissioner.
DOWNSTREAM LEADERSHIP CHANGES
FDA may also see additional leadership changes in the coming months, following a period of substantial leadership and staffing changes over the past two years. For example, the day after the election, FDA Chief Counsel Sean Keveney announced he would be stepping down after a replacement is identified. It is possible that we may also see additional director-level changes. For instance, FDA’s Human Foods Program (HFP) is currently led by Acting Deputy Commissioner for Food Donald Prater, who took the position when the former deputy commissioner, Kyle Diamantas, was named acting FDA commissioner. Given the high-profile food recalls over the past year, there may be congressional pressure to name a permanent Deputy Commissioner for Food, especially once a new FDA commissioner has been confirmed.
On the other hand, FDA’s medical product centers are generally perceived to have stabilizing leaders in place for each of the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), and the Center for Biologics Evaluation and Research (CBER), making major leadership changes in these centers less likely.
CONGRESSIONAL OVERSIGHT OF FDA AND REGULATED INDUSTRY
With significant movement within Congress resulting from this year’s midterm elections, changes to the leadership and membership of key congressional committees overseeing FDA and its regulated industry are expected in the new year. FDA’s key oversight committees, including the Senate HELP committee and the House Committee on Energy and Commerce (E&C), are expected to have significant shifts in membership and leadership. Leadership and membership changes will shift the committees’ priorities and approaches to oversight of FDA and regulated industry alike. With scheduled reauthorizations of FDA’s medical products user fee agreements, focus by these committees on FDA issues through the end of the fiscal year would be expected as part of any reauthorization cycle.
USER FEE REAUTHORIZATIONS
FDA’s current user fee acts, including the Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), Biosimilar User Fee Act (BsUFA), and Medical Device User Fee Act (MDUFA), are up for congressional reauthorization, with the current acts expiring on September 30, 2027. Despite the shifts in Congress, it is expected that these acts will pass, given that they are considered essential legislation, accounting for a significant portion of FDA’s annual budget.
However, the “must-pass” nature of these bills also presents the opportunity for members to add legislative riders. These could be used to revisit or modify FDA and other health policies adopted over the past two years, or to advance new policies on issues that may attract bipartisan support, such as competition from Chinese drug developers and prescription drug advertising. In addition, proposed legislative riders have, in past reauthorization cycles, complicated and delayed reauthorization.
MEDICAL PRODUCT AREAS OF HEIGHTENED INTEREST
In recent years, several product categories have been the subject of heightened public and governmental interest, including vaccines, reproductive health, peptides, and psychedelics. While executive branch positions on these product classes may remain unchanged, congressional attention to and oversight of FDA’s regulation of these classes may shift as a result of midterm elections.
For example, FDA’s safety assessment of mifepristone remains ongoing, receiving congressional attention in recent years, which may continue going forward, even if the mix and positions of congressional voices shift. In other areas, including in the regulation of vaccines, peptide products, and psychedelics, where FDA has instituted new policies and taken actions in response to executive-level priorities, new leadership and membership of the Senate HELP and House E&C committees may also shift Congress’s attention to these issues.
AI AND DIGITAL HEALTH
Since January 2025, the US administration and FDA have prioritized accelerating AI innovation and reducing regulatory barriers, primarily through executive orders and nonbinding guidance. Changes in congressional leadership following the midterm elections could bring increased scrutiny of FDA’s deregulatory approach for digital health and AI-enabled devices, including evaluating whether increased FDA oversight may be necessary to protect patient safety and public health. Growing scrutiny of the relationship between the technology industry and government regulators, such as FDA, may be another area of focus for congressional oversight.
Key areas to watch include FDA enforcement discretion policies, including FDA’s January 2026 updates to the Clinical Decision Support Software and General Wellness guidance documents, which expanded enforcement discretion without prior public comment (discussed in our prior blog post). Other areas that may face further scrutiny, particularly as autonomous AI capabilities expand, include issues related to algorithmic bias and data provenance, such as the quality and representativeness of training and validation datasets, algorithmic performance across patient populations, and transparency regarding algorithmic limitations.
The upcoming MDUFA VI reauthorization process could provide an opportunity for Congress to consider whether statutory changes are warranted to address emerging AI and digital health technologies, such as enhancements to Predetermined Change Control Plans and postmarket reporting requirements.
DRUG PRICING
(MFN, TrumpRx, and Manufacturer Agreements)
Pharmaceutical manufacturers should anticipate heightened congressional scrutiny of the US administration’s drug pricing initiatives, particularly its most-favored-nation (MFN) pricing policies, manufacturer-specific pricing agreements, and TrumpRx platform. Although the administration has pursued lower prescription drug prices through direct negotiations with pharmaceutical manufacturers and voluntary agreements intended to align US prices more closely with those in other developed countries, Democratic lawmakers may question the transparency, enforceability, and long-term effectiveness of these arrangements, particularly where the terms remain confidential or offer manufacturers regulatory or other concessions.
Democratic control of key congressional committees could accelerate the pace of hearings, investigations, and document requests examining the financial terms of manufacturer agreements, the extent to which negotiated discounts actually benefit patients, and the relationship between MFN policies and existing federal drug pricing programs. Pharmaceutical manufacturers should therefore prepare for increased congressional oversight and demands for transparency regarding their pricing practices, agreements with the federal government, and patient access initiatives, particularly as lawmakers assess whether the administration’s drug pricing initiatives are delivering meaningful savings to patients.
INFLATION REDUCTION ACT DRUG PRICE NEGOTIATIONS
Pharmaceutical manufacturers may see renewed congressional interest in efforts to strengthen and expand the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act (IRA), particularly as changes in congressional membership could create opportunities to revisit statutory limitations on the program’s scope and implementation. Building on the IRA’s existing framework, such efforts could include increasing the number of drugs subject to negotiation, accelerating the timeline for negotiation eligibility, or narrowing existing exemptions.
Although major statutory changes could face opposition, Democratic control of congressional committees could lead to increased oversight of the Centers for Medicare & Medicaid Services’ implementation of the program, including drug selection, maximum fair price determinations, manufacturer compliance, and the impact of negotiated prices on Medicare beneficiaries. Pharmaceutical manufacturers should therefore continue preparing for successive negotiation cycles while monitoring legislative proposals that could expand the program’s reach or alter its financial implications for existing and pipeline products. US Senator Ron Wyden (D-OR) has supported efforts to expand Medicare drug price negotiations under the IRA, including proposals to increase the number of drugs subject to negotiation.
FOOD REGULATION
Over the past two years, FDA has taken substantial actions in the area of food regulation, which we expect to continue under the new Congress given the bipartisan nature of food safety issues. These include the current FDA proposal to reform the Generally Recognized as Safe (GRAS) process, FDA actions with respect to certain color additives, proposed nutrient limits and labeling rules for infant formula, and the US Department of Agriculture’s definition for ultra-processed foods that remains under regulatory review. Congress may further undertake legislative action in this space, especially given the proliferation of state-level laws.
MARIJUANA RESCHEDULING:
Following the April 2026 final rule moving certain FDA-approved and state-licensed medical marijuana products from Schedule I to Schedule III and the summer 2026 evidentiary hearings on broader marijuana rescheduling (as detailed in our prior LawFlash), stakeholders should monitor whether advancing and defending these initiatives remains a priority for the US Department of Justice and DEA amid shifting congressional oversight and legislative priorities following the midterm elections.
Key developments to watch include the impact of legal and procedural challenges on DEA’s momentum, implementation of the new federal registration pathway for state-licensed medical marijuana entities, and the timing of the DEA administrative law judge’s forthcoming recommended decision and the DEA administrator’s final determination on broader Schedule III placement.
LOOKING AHEAD
As the new Congress takes shape, the extent to which shifting congressional priorities translate into meaningful changes to FDA policy and operations remains uncertain. While the administration is likely to continue advancing its existing regulatory agenda, changes in congressional leadership, oversight priorities, and legislative dynamics could influence both the pace and direction of FDA policymaking.
With significant leadership transitions potentially ahead and several must-pass legislative initiatives on the horizon, including the 2027 user fee reauthorizations, life sciences stakeholders should continue monitoring developments that could affect FDA’s regulatory framework and priorities.
Law clerk Joshua Yao contributed to this LawFlash.
HOW WE CAN HELP
Morgan Lewis guides and provides strategic counseling for life sciences companies navigating regulatory and legal changes, with experience at both the state and federal levels.